An interventional study of Standardized breakfast and Standardized snack in Gestational Diabetes Mellitus, Intrauterine Hyperglycemia and Birth Outcome, Adverse, sponsored by Westlake University. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Westlake University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.
Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 16th largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2023, is one of 36 with no phase, reaches primary completion later than 8 of the 22 other live ones, and was the 52nd registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:
Yang ZHANG · Sites in China
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Peking University · Sites in China
Ages 18+ · Healthy volunteers
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–50 · Women only
Peking Union Medical College Hospital · Sites in China
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 291 across the 39 interventional studies, 1,122 across the 29 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 68 has an industry lead sponsor. The 10 most frequent:
Westlake University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Westlake University has 3 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234332Peking UniversityPeking University Birth Cohort in Weifang (PKUBC-WF) | 2026-12-31 |
| NCT07119177Yang ZHANGLong-term Evaluation of Gestational Endocrine & Metabolic Dynamics | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Diabetes, Gestational with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Wenzhou Gestational Diabetes Cohort (WGDC) is a prospective cohort study among women with gestational diabetes mellitus (GDM) during pregnancy and their offspring living in Wenzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with GDM over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of the WGDC is to investigate the association of dietary and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the patients with long-term metabolic health of the women and their offspring.
In China, an alarming increase in the prevalence of GDM has been observed in the past decade. GDM is of concern because it is associated with several maternal and fetal medical disorders. Lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of GDM. However, the associations between dietary intake and physical activity and health outcomes for GDM women and their children remain unclear due to subjective measurements of diet and physical activity. Recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. In addition, for the same food and physical activity exposure, GDM women may have different blood glucose responses, but the nature of variation is currently poorly characterized. Therefore, the present WGDC design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both Food Frequency Questionnaire and daily dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. We will then follow up these women participants during and after this pregnancy, and also follow up their offspring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)
Other: Standardized breakfast
Tomato (50g) and skim milk (200g)
Other: Standardized snack
Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)
Other: Standardized lunch
Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
Continuous blood glucose change over 2 weeks
Glucose levels are assessed by continuous glucose monitoring over 2 weeks.
Time frame: two weeks after enrollment
Adverse birth outcomes
Number of participants with adverse birth outcomes, such as, preterm birth, macrosomia and neonatal hypoglycemia.
Time frame: 9-12 weeks after enrollment
Weight changes during early childhood
Weight in kilograms
Time frame: at delivery, age of 6 months, 1 year, 3 years and 6 years
Number of participants developing type 2 diabetes
Risk of developing type 2 diabetes after the delivery of the women with gestational diabetes.
Time frame: 6 years and 10 years after delivery
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Nov 2025, 31 months.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's 31 months is above that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Mar 2026 → Nov 2025 and completion Mar 2033 → Mar 2035.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Westlake University